Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
Advertisement
Articles by Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Popat on the DREAMM-1 Trial in Relapsed/Refractory Multiple MyelomaNovember 27th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5